Clinical Trial Update: Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab to modulate the gut microbiome after chemotherapy in resectable pancreatic cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Pancreatic Cancer | Phase 2 | Status: RECRUITING